Hyppää sisältöön
    • Suomeksi
    • In English
  • Suomeksi
  • In English
  • Kirjaudu
Näytä aineisto 
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
  •   Etusivu
  • 3. UTUCris-artikkelit
  • Rinnakkaistallenteet
  • Näytä aineisto
JavaScript is disabled for your browser. Some features of this site may not work without it.

Effects of Cholinesterase Inhibitor Medication on QTc Interval in Memory Clinic Patients

Isotalo, Hanna Karita; Lehtovaara, Joanna Karoliina; Ekblad, Laura Linnea; Nuotio, Maria Susanna; Langén; Ville Lauri Johannes

Effects of Cholinesterase Inhibitor Medication on QTc Interval in Memory Clinic Patients

Isotalo, Hanna Karita
Lehtovaara, Joanna Karoliina
Ekblad, Laura Linnea
Nuotio, Maria Susanna
Langén
Ville Lauri Johannes
Katso/Avaa
isotalo-et-al-2025-effects-of-cholinesterase-inhibitor-medication-on-qtc-interval-in-memory-clinic-patients.pdf (1.578Mb)
Lataukset: 

SAGE PUBLICATIONS INC
doi:10.1177/10600280251328530
URI
https://journals.sagepub.com/doi/epub/10.1177/10600280251328530
Näytä kaikki kuvailutiedot
Julkaisun pysyvä osoite on:
https://urn.fi/URN:NBN:fi-fe2025082791781
Tiivistelmä

Background: Cholinesterase inhibitors (ChEIs)-donepezil, rivastigmine, and galantamine-are beneficial in treating Alzheimer disease (AD). However, due to their impact on extra-cerebral acetylcholine signaling, concerns about cardiac adverse effects, including QT interval prolongation, persist. Despite this, evidence-based guidelines for electrocardiogram (ECG) monitoring during ChEI treatment are lacking, and prior studies on ChEIs and corrected QT intervals (QTc) yield inconsistent findings.

Objective: This study aimed to investigate the association between ChEI use and changes in QTc intervals among older adults.

Methods: We collected retrospective data from first-time visitors to the geriatric memory clinic of Turku City Hospital in 2017 and 2019. We included patients who were newly prescribed ChEIs and had ECG data available (n = 126, mean age 81.1 years, 56.3% female). QTc prolongation was defined as >= 460 ms in females and >= 450 ms in men. Paired t tests compared QTc means before and during ChEI use, and McNemar tests analyzed changes in the proportion of prolonged QTc.

Results: Mean +/- SD QTc (ms) before versus during ChEI use was: 420.8 +/- 24.0 versus 423.9 +/- 28.0 (P = .13) for donepezil; 416.0 +/- 20.4 versus 416.5 +/- 26.1 (P = .92) for galantamine; 416.1 +/- 22.3 versus 409.6 +/- 20.1 (P = .30) for rivastigmine; and 419.7 +/- 23.4 versus 421.5 +/- 27.3 (P = .34) for all ChEIs. Prolonged QTc occurred in 7.9% of patients before versus 12.7% during ChEI use (P = .21).

Conclusion and Relevance: We found no statistically significant association between ChEI use and QTc interval prolongation or an increased proportion of pathological QTc values during ChEI treatment. Larger studies are warranted to establish evidence-based recommendations on ECG monitoring during ChEI medication.

Kokoelmat
  • Rinnakkaistallenteet [27094]

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste
 

 

Tämä kokoelma

JulkaisuajatTekijätNimekkeetAsiasanatTiedekuntaLaitosOppiaineYhteisöt ja kokoelmat

Omat tiedot

Kirjaudu sisäänRekisteröidy

Turun yliopiston kirjasto | Turun yliopisto
julkaisut@utu.fi | Tietosuoja | Saavutettavuusseloste